Company: ZVRA
Filing Date: 2025-04-29
Form Type: DEFC14A
Source: 0000897069-25-000885
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-29
Form: DEFC14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 _____________________________________ SCHEDULE 14A (RULE 14a-101)
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(AMENDMENT NO.) _____________________________________ Filed by the Registrant ☐Filed by a Party other than the Registrant ☒ Check the appropriate box:

| ☐                                                | Preliminary Proxy Statement                                                     |
| ☐                                                | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒                                                | Definitive Proxy Statement                                                      |
| ☐                                                | Definitive Additional Materials                                                 |
| ☐                                                | Soliciting Material Under Rule 14a-12                                           |
| Zevra Therapeutics, Inc.                         |                                                                                 |
| (Name of registrant as specified in its charter) |                                                                                 |

DANIEL J. MANGLESS
TRAVIS C. MICKLE, PhD
ARTHUR C. REGAN
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) -with copies to- Peter D. Fetzer Foley & Lardner LLP
777 East Wisconsin Avenue Milwaukee, WI 53202-5306 (414) 297-5596 Payment of Filing Fee (Check all boxes that apply):

| ☒ | No fee required                                                                                     |
| ☐ | Fee paid previously with preliminary materials                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

2025 ANNUAL MEETING OF STOCKHOLDERS OF ZEVRA THERAPEUTICS, INC. PROXY STATEMENT OF DANIEL J. MANGLESS
TRAVIS C. MICKLE, PhD
ARTHUR C. REGAN April 29, 2025 To Our Fellow Stockholders of Zevra Therapeutics, Inc.: This Proxy Statement is furnished to holders of the common stock, par value $0.0001 per share (“ Common Stock”), of Zevra Therapeutics, Inc. (“ Zevra” or the “ Company”), located at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747, in connection with our solicitation of proxies for use at the 2025 Annual Meeting of Stockholders of